Tumor angiogenesis is of paramount importance in solid tumor development. Elevated serum levels of YKL-40, which is a secreted heparin-binding glycoprotein, have been associated with a worse prognosis from various advanced human cancers. Yet the role of YKL-40 activity in these cancers is still missing. In this study, we showed that ectopic expression of YKL-40 in MDA-MB-231 breast cancer cells and in HCT-116 colon cancer cells led to larger tumor formation with an extensive angiogenic phenotype than did control cancer cells in mice. Affinity-purified recombinant YKL-40 protein promoted vascular endothelial cell angiogenesis in vitro, the effects of which are similar to the activities observed using MDA-MB-231 and HCT-116 cellconditioned medium after transfection with YKL-40. Furthermore, YKL-40 was found to induce coordination of membrane-bound receptor syndecan-1 and integrin a v b 3 and to activate an intracellular signaling cascade, including focal adhesion kinase and mitogen-activated protein kinase extracellular signal-related kinase1/2 in endothelial cells. Moreover, blockade of YKL-40 using small-interfering RNA gene knockdown suppressed tumor angiogenesis in vitro and in vivo. Immunohistochemical analysis of human breast cancer showed a correlation between YKL-40 expression and blood vessel density. These findings provide novel insights into angiogenic activities and molecular mechanisms of YKL-40 in cancer development.
Introduction
The development of human cancers involves multiple pathological events through which cancerous cells gain the ability to overcome adverse stress imposed by adjacent normal tissues. During this process, the intrinsic genomic instability of cancerous cells induces a number of genetic and epigenetic alterations that enable them to proliferate, survive and invade. Once they expand to a critical level, cancerous cells find a way to promote new vasculature development, a process known as tumor angiogenesis, to progress and metastasize (Hanahan and Folkman, 1996; Hanahan and Weinberg, 2000) . Tumor angiogenesis, an integral part of solid tumor development, provides nutrients and oxygen in a hypoxic microenvironment formed in the centers of growing tumors and facilitates tumor cell proliferation by enhancing oxygenation and removing metabolic wastes, which would normally induce necrosis. A number of angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor have been shown to have critical roles in the development of tumor vasculature (Kim et al., 1993; Yancopoulos et al., 2000; Fahmy et al., 2003) . However, much more remains to be understood about the molecular nature of unidentified factors that are also believed to have the ability to promote angiogenesis in the development of various human cancers.
YKL-40 (also known as human cartilage-glycoprotein 39 or Chitinase 3-like 1) is a 40-kDa secreted glycoprotein that was discovered as a heparin-binding protein in the conditioned medium of human synoviocytes, chondrocytes and MG-63 osteosarcoma cell line (Johansen et al., 1992; Hakala et al., 1993; Shackelton et al., 1995) . Although YKL-40 is a member of the chitinase gene family that can bind oligosaccharide, it does not have chitinase activity because of the substitution of an essential glutamic acid with leucine in the chitinase-3-like catalytic domain (Renkema et al., 1998; Fusetti et al., 2003) . Therefore, its physiological or pathological function remains enigmatic. Given the evidence that serum levels of YKL-40 were elevated in patients with multiple chronic inflammatory diseases (Johansen et al., 2000; Sharif et al., 2006) , its function is speculated to be associated with tissue remodeling.
Over the past decade, considerable attention has been focused on a potential role of YKL-40 in the development of various human cancers. Gene microarray analyses and SAGE (serial analysis of gene expression) database showed significantly higher expression levels of YKL-40 in carcinoma tissues collected from the ovary, brain and breast than those observed in adjacent normal tissues (Lal et al., 1999; Lau et al., 2006) . A multitude of clinical studies have shown that serum levels of YKL-40 were elevated in patients with a series of carcinomas (Cintin et al., 2002; Jensen et al., 2003; Johansen et al., 2004) . For instance, clinical data studying brain tumors indicate that glioblastomas, which exhibit striking angiogenesis, contain considerably elevated YKL-40 levels both in tumor tissue and in blood (Nigro et al., 2005; Hormigo et al., 2006) . Taken together, these data suggest that serum levels of YKL-40 may serve as a cancer biomarker. Nonetheless, little is known regarding YKL-40 activity in human cancers.
In this study, we tested the hypothesis that YKL-40 acts as an angiogenic factor to promote tumor growth and angiogenesis. We found that YKL-40 ectopically expressed by breast and colon cancer cells induces tumor angiogenesis and tumor development. The molecular mechanisms underlying YKL-40-induced angiogenesis involve the coactivation of membrane receptor syndecan-1 (S1) and integrin a v b 3 , as well as downstream signaling effectors focal adhesion kinase (FAK) and mitogen-activated protein kinase (MAPK). Furthermore, elevated YKL-40 expression in human breast cancer is associated with blood vessel formation. These findings may shed light on the angiogenic signature of YKL-40 in the pathogenesis of a wide range of human cancers.
Results

YKL-40 promotes tumor growth and blood vessel formation
To explore a possible role of YKL-40 in cancer development, we created a full-length YKL-40 cDNA from the osteosarcoma line, MG-63 (Supplementary Figure 1) . We began to evaluate endogenous expression levels of YKL-40 in a number of cell lines, including immortalized human microvascular endothelial cells (HMVECs), 293T cells, breast cancer cells MCF-7, T47D and MDA-MB-231, as well as in colon cancer cells HCT-116. In the prescreening of these lines by both PCR and western blot analysis, YKL-40 expression was found to be restricted to MG-63 cells (Figure 1a) . The absence of endogenous YKL-40 in the other lines provided a null background against which biological activities of YKL-40 were examined. To monitor its functional behavior in cancer cells, colon cancer cell line HCT-116 and breast cancer cell line MDA-MB-231 were engineered to ectopically express YKL-40 through a retroviral infection system. In this manner, we generated populations of cancer cells that stably express ectopic YKL-40. As shown by western blot analysis using cellcultured medium (Figure 1b) , YKL-40 was released from these cell lines and the levels of YKL-40 in cell lysates were below the limit of detection (data not shown), supporting the fact that YKL-40 is a secreted protein.
To determine whether YKL-40 can enhance the proliferation of HCT-116 and MDA-MB-231 cells once they acquired the expression of YKL-40, we monitored 3 H-thymidine incorporation into the DNA of dividing cells. Unexpectedly, proliferation was not significantly altered by the introduction of the YKL-40 gene into either cell type (Supplementary Figure 2) . The inability to increase cell division was also observed in the testing of these parental cancer cell lines treated with recombinant protein YKL-40 (data not shown). We next wanted to determine whether YKL-40 could influence tumor growth and development in vivo. HCT-116 and MDA-MB-231 cells overexpressing YKL-40 were subcutaneously injected into SCID/Beige mice and tumor growth was monitored weekly for up to 6 weeks ( Figure 2a) . No palpable tumors were discernable until week 2. From the third week onwards, both YKL-40-expressing cancer cell lines rapidly developed palpable tumors relative to control tumor cells. By week 6, YKL-40-expressing MDA-MB-231 and HCT-116 cells caused four and eightfold larger tumors than tumors formed from their corresponding control cells. Interestingly, tumors developed from YKL-40-expressing cells showed an extensive arbor of ramified blood vessels on the tumor surface as compared with relatively few vessels observed in control tumors (Figure 2b ), suggesting that Figure 4) . YKL-40 tagged with 6xhis was specifically detectable in western blot analysis using an anti-YKL-40 (known as rAY, generated from our laboratory) and an anti-his polyclonal antibody. The affinity-purified recombinant protein YKL-40 was then engaged to test its activities in endothelial cell angiogenesis. Unlike VEGF, recombinant YKL-40 exerted a modest effect on the proliferation of HMVECs (B25% increase in cell proliferation, data not shown). However, YKL-40 resembled VEGF angiogenic properties, one of the most potent angiogenic factors, by inducing endothelial cell migration and tube formation (Figures 3a and b) . The migration and tube formation induced by recombinant YKL-40 were approximately three to four times greater than were observed in control cells, similar to VEGF. A short peptide of YKL-40 (ySP) that contains 20 amino acids of YKL-40 failed to induce angiogenesis, serving as an isotype control. These data support the hypothesis that YKL-40 has the ability to stimulate angiogenic responses in endothelial cells.
In an attempt to determine whether YKL-40 derived from cancer cells promotes endothelial cell angiogenesis in a paracrine manner in tumor in vivo, we used a cell coculture system. Conditioned media derived from both MDA-MB-231 and HCT-116 cells ectopically expressing YKL-40 or vector were introduced to HMVECs, and then endothelial cell angiogenic activity including cell migration and tube formation was analysed. As shown in Figure 3c , the media from both cancer cells expressing ectopic YKL-40 displayed the same effects, as did recombinant YKL-40 on the induction of endothelial cell angiogenesis (Figures 3a and b) . Moreover, an inclusion of the anti-VEGF antibody failed to protect YKL-40 activities ( Figure 3c ). Collectively, all the data demonstrate the novel angiogenic activity for YKL-40, independent of VEGF.
YKL-40 induces coupling of S1 with integrin a v b 3 To test whether YKL-40 can bind to heparin, we used a heparin-Sepharose affinity binding assay and found that YKL-40 bound directly to the affinity column (Figure 4a ), consistent with previous reports (Shackelton et al., 1995; Fusetti et al., 2003) . We next questioned whether YKL-40 acts on endothelial cells by activating the transmembrane receptor S1, a proteoglycan that is the major source of cell surface heparan sulfate (HS). HS is known to function as a key mediator connecting membrane-associated receptors with extracellular heparin-binding proteins, such as extracellular matrix protein (such as vitronectin) and angiogenic factors (such as basic fibroblast growth factor and VEGF) (Bernfield et al., 1999 (Bernfield et al., , 2004 . Moreover, there is compelling evidence showing that endowed with the HS chain on its ectodomain, S1 acts as a matrix co-receptor with adjacent membrane-bound receptors, such as integrins to mediate cell adhesion and/or spreading (McQuade et al., 2006) . In an attempt to test whether YKL-40 has the ability to induce cooperation of S1 with co-membrane receptor integrins, we investigated the physical interaction between S1 and integrin a v b 3 or a v b 5 upon YKL-40 stimulation using co-immunoprecipitation and western blot analysis. Protein levels of both S1 and integrin a v b 3 and a v b 5 in HMVECs were detectable (data not shown). Exposure of HMVECs to YKL-40 resulted in a dramatic increase in the association of S1 with integrin b 3 , but this event did not occur in the treatment with ySP as a control ( Figure 4b ). As expected, this interaction was prevented by pretreatment with heparitinase (Hep) and chondroitinase ABC (Chon) that function to remove cell surface glycosaminoglycans. S1 did not collaborate with integrin b 5 when an anti-integrin b 5 antibody replaced b 3 antibody in the co-immunoprecipitation, validating the specificity of receptor coordination between integrin a v b 3 and S1 in response to YKL-40. To further define the functional role of this co-receptor interaction in YKL-40-induced angiogenesis, we examined cell adhesion and spreading that are directly regulated by the coupling of syndecans with integrins (Beauvais et al., 2004) . As shown in Figure 4c , HMVECs plated in the absence of serum had greater potential to adhere to and spread on wells coated with YKL-40 than on ySP-coated wells. However, incubation with either a heparitinase/chondroitinase ABC or neutralizing anti-integrin a v b 3 antibody (LM609) abrogated YKL-40 effects on cell spreading, whereas an anti-integrin a v b 5 antibody (P1F6) failed to block this activity. Again, the analysis on tube formation showed the same profile as the one tested in cell spreading (Figure 4d ), highlighting the essential role of the collaboration of S1 with integrin a v b 3 in YKLinduced endothelial cell angiogenesis.
We then sought to test whether only S1, but not other family members of syndecans, mediates YKL-40-induced angiogenesis. The small-interfering RNA (siR-NA) approach designed to specifically target the ectodomain of S1 (S1 siRNA) (Beauvais et al., 2004) was engaged in HMVEC. Transfection with S1 siRNA efficiently silenced S1 expression in the cells (Figure 5a) . Suppression of the S1 gene resulted in a significant decrease in S1 coupling with integrin a v b 3 compared with their receptor association seen in control cells ( Figure 5b) . As with the deficiency in the membraneassociated receptor collaboration in siRNA cells, functional analysis with tube formation showed that silencing of the S1 gene abolished the effects of YKL-40 on endothelial cell activation (Figure 5c ), confirming that S1 has a key role in mediating endothelial cell angiogenesis induced by YKL-40.
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Activities of FAK and MAPK are required for YKL-40-induced angiogenesis As one of the key factors mediating integrin signaling, FAK is shown to transmit signaling to downstream effectors in cells to evoke angiogenic responses (Hood et al., 2003) . To test whether FAK is activated by YKL-40, we stimulated HMVEC with YKL-40 and cell lysates were measured for the expression levels of 
C o n t r o l A n t i -V E G F Y K L -4 0 Y K L -4 0 + a n t i -V E G F C o n t r o l A n t i -V E G F Y K L -4 0 Y K L -4 0 + a n t i -V E G F
Figure 3 YKL-40 stimulates endothelial cell angiogenesis in culture. (a) Human microvascular endothelial cells (HMVECs) were loaded into the upper chamber of a transwell and a short peptide of YKL-40 (ySP) (100 ng/ml), YKL-40 (100 ng/ml) or vascular endothelial growth factor (VEGF) (10 ng/ml) was introduced into the lower chamber for migration assay. Cells migrated into the membrane were quantified. n ¼ 5. *Po0.05 compared with the control or ySP group. (b) HMVECs were loaded on a layer of Matrigel and cultured overnight in the presence of ySP (100 ng/ml), YKL-40 (100 ng/ml) or VEGF (10 ng/ml) for tube formation analysis. Vessel-like network was quantified. n ¼ 4-5. *Po0.05 compared with control or ySP group. (c) Conditioned media (CM) derived from MDA-MB-231 and HCT-116 cells expressing YKL-40 or control vector were transferred into the HMVEC culture in the presence of an anti-VEGF antibody (1 mg/ml) to evaluate their effects on endothelial cell migration and tube formation. n ¼ 6. *Po0.05 compared with controls. , mediates angiogenic responses (Yan et al., 2008) , FAK pY 861 was found to act as a key mediator to trigger angiogenic signaling cascades in endothelial cells as the activated form of FAK pY 861 was increased by YKL-40 in as early as 5-10 min (Figure 5d ). In addition, the downstream effectors pErk1/2 (Phospho-Erk1/2) were induced similarly. Furthermore, this signaling initiated through the activation of integrin a v b 3 , other than a v b 5 , was validated by the study using anti-integrin neutralizing antibodies (Figure 5d ). To identify the functional role of Erk1/2 in YKL-40-induced angiogenesis, we examined the effects of YKL-40 on tube formation in the presence of PD98059, an inhibitor of Erk1/2 (Figure 5e 1 U/ml)/chondroitinase (Chon 0.1 U/ml) or those heat-inactivated (HI) enzymes for 2 h before stimulation with YKL-40 or ySP (100 ng/ml) for 10 min. Cell lysates were subjected to imunoprecipitation with anti-integrin b 3 or b 5 antibody, followed by immunoblotting using anti-S1 antibody. (c) After treatment with Hep/Chon or HI as indicated in panel b, cells were introduced to the plates precoated with YKL-40 or a short peptide of YKL-40 (ySP) (10 mg/ml) in the absence or presence of LM609 or P1F6 (10 mg/ml, Chemicon) for 2 h. The cells were then fixed and stained with rhodamine-conjugated phalloidin. Bar: 10 mm. (d) After treatment with Hep/Chon or HI as indicated in panel b, cells were applied to Matrigel for analysis of tube formation in the absence or presence of YKL-40 (100 ng/ml), ySP (100 ng/ml), LM609 (10 mg/ml) or P1F6 (10 mg/ml). n ¼ 4. *Po0.05 compared with corresponding control cells treated with ySP.
þ Po0.05 compared with cells treated with YKL-40 alone.
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The inhibitory activity of YKL-40 siRNA1 and siRNA2 was also observed in the testing of endothelial cell migration (Figure 6b ). These results indicate that U87-secreted YKL-40 similar to the affinity-purified recombinant protein YKL-40 described earlier is capable of inducing endothelial cell angiogenesis. Next, we questioned whether YKL-40 gene knockdown can influence tumor growth and angiogenesis in vivo. To test this, we analysed tumor development by the injection of U87 cells expressing vector, YKL-40 siRNA1, or siRNA2 into SCID/Beige mice ( Figure 6c ). As expected, both siRNA1 and siRNA2 knockdown of YKL-40 in U87 cells notably suppressed tumor growth as tumor volume was reduced to B30% of that observed in the control animals on week 6 (Figure 6c ). Moreover, immunohistochemical analysis showed that the vessel density of siRNA1 and siRNA2 tumors was B56% of the vasculature that was found in control tumors (Figure 6d ). All the results were consistent with in vivo data from earlier xenograft models in which tumor cells were enforced to express ectopic YKL-40, validating the angiogenic activity of YKL-40 in tumor development in vivo. Figure 5 Small-interfering RNA (siRNA) knockdown of S1 and angiogenic signaling cascade in endothelial cells. (a) Western blot analysis showed S1 gene knockdown in the cells. siRNA targeted the ectodomain of S1. (b) Control and siRNA S1 endothelial cells were stimulated with YKL-40 or a short peptide of YKL-40 (ySP) (100 ng/ml) for 10 min and then cell lysates were subjected to immunoprecipitation and immunoblotting as described in Figure 4 . (c) Control and siRNA S1 cells were used for tube formation in the presence of YKL-40 or ySP (100 ng/ml). n ¼ 3. *Po0.05 compared with control cells treated with ySP.
þ Po0.05 compared with cells treated with YKL-40 alone. (d) Human microvascular endothelial cells (HMVECs) pretreated with serum-free medium were stimulated with YKL-40 (100 ng/ml) from 5 to 30 min. Cell lysates were collected for analysing phosphorylated levels of focal adhesion kinase (FAK) and extracellular signal-related kinase-1/2 (Erk1/2) by immunoblotting using anti-FAK, FAK pY 397 , FAK pY 861 , Erk and phospho-Erk1/2 (pErk1/2). In some conditions, HMVECs were pretreated with LM609 or P1F6 (10 mg/ml) for 15 min and then stimulated with YKL-40 (100 ng/ml) for 10 min. (e) HMVECs were measured for tube formation in the presence of YKL-40 (100 ng/ml) and/or PD98059 (10 mM). n ¼ 3. *Po0.05 compared with control cells. Cancer cases were categorized into three groups according to the expression levels of YKL-40 (negative/low: n ¼ 20; medium: n ¼ 9; and high: n ¼ 9) as described in the 'Materials and methods' section. Blood vessel density in each case was quantified with an average of CD34 arbitrary density numbers from six to eight fields using an NIH image analysis program. Red bars indicate the average levels of CD34 density. (c) All of cancer cases were plotted to analyse the relationship between expression levels of YKL-40 and CD34 density by the software of Significance of a Correlation Coefficient.
YKL-40 and tumor angiogenesis R Shao et al expressing low YKL-40, respectively (Figure 7b) . Furthermore, correlation analysis showed that YKL-40 expression levels directly correlated with CD34 density (Figure 7c ). Taken together, all lines of evidence identifying the angiogenic signature of YKL-40 from both in vivo and in vitro studies have strongly supported our hypothesis that YKL-40 acts as an angiogenic factor to promote tumor growth and development.
Discussion
Our studies have adopted a multidisciplinary approach to show a novel angiogenic signature for YKL-40 and to identify mechanisms by which YKL-40 promotes tumor growth and development. These findings show a fundamental mechanism for the phenomena reported previously that elevated serum levels of YKL-40 are associated with poorer prognosis and shorter diseasefree survival in patients with a broad range of cancers, including breast (Jensen et al., 2003) , colorectal (Cintin et al., 2002) , ovarian (Hogdall et al., 2003) , prostate (Brasso et al., 2006) , small-cell lung (Johansen et al., 2004) , malignant melanoma (Schmidt et al., 2006) , glioma (Pelloski et al., 2005) and acute myeloid leukemia (Bergmann et al., 2005) . In addition, the SAGE database also shows that the YKL-40 transcript is overexpressed in a number of cancer tissues compared with adjacent normal controls, such as mammary, ovary and brain tissues (http://cgap.nci.nih.gov/). Immunohistochemical analysis of breast cancer tissue in this study, which displays a correlation of YKL-40 expression levels with blood vessel density, has provided direct evidence, indicating the pathological role of YKL-40 in the development of human cancers. It would be quite interesting to know whether there is an intimate association between tissue expression levels and serum concentrations of YKL-40 in the same cancer patients. Should YKL-40 expression in the cancer tissue be the determinant of its concentrations in blood, testing of serum levels of YKL-40 as a cancer biomarker might have immense value in cancer diagnosis and prognosis. Recent attention has been focused on the relationship between YKL-40 expression and clinical outcome in breast cancer, although the data are inconsistent because some evidence shows the correlation between increased expression levels of YKL-40 and decreased disease-free survival, but the others do not (Kim et al., 2007; Roslind et al., 2008) . An epidemiological study with a substantial sample size seems to be necessary to elucidate the association of expression levels of YKL-40 with metastasis, severity or outcome of breast cancer. Results presented in this study, however, have provided a valuable insight into molecular mechanisms by which YKL-40 stimulates tumor development.
The first 22 amino acid residues at the N-terminal sequence of YKL-40 constitute the signal peptide that ensures the secretion of mature protein YKL-40 (Nyirkos and Golds, 1990; Johansen et al., 1992) . As YKL-40 does not have an RGD domain, it cannot directly bind to integrins on the cell membrane.
However, YKL-40, a heparin-binding protein (Shackelton et al., 1995; Hu et al., 1996; Fusetti et al., 2003) , contains putative arginine-lysine (RK)-rich domain(s), the motif that has been shown to be important for heparin binding in other angiogenic factors, such as aFGF, basic fibroblast growth factor and VEGF (Higashiyama et al., 1991; Maglione et al., 1993; Albini et al., 1996) . Similar to heparin-binding protein vitronectin (VN) and basic fibroblast growth factor the activities of which largely depend on the presence of HS (Bernfield et al., 1999; Beauvais et al., 2004) , YKL-40 was found to induce the collaboration of membrane receptor S1 with integrin a v b 3 through binding to HS and then trigger intracellular signaling cascades. Several lines of evidence have shown that syndecans act as matrix co-receptors with integrins to mediate cell binding and signaling on ligands that contain HS (Beauvais and Rapraeger, 2003; Beauvais et al., 2004; McQuade et al., 2006) . Our results, as with these findings, strongly suggest that S1 in collaboration with integrins is a critical regulator of cell motility in vascular endothelial cells the functions of which are dependent on the activity of integrin a v b 3 and/or a v b 5 . It is also quite possible that there are receptors specific for YKL-40 binding present on endothelial cells that are currently unknown. However, the heparin-binding property of YKL-40 may also be indispensable in the affinity binding and activation of these specific receptors if they also contain HS chains on ectodomains. The current evidence identifying signaling pathways by the activation of membrane receptors further strengthens a paradigm that the cross-talk between adjacent membrane-anchored receptors has a key role in transmitting 'outside-in' signaling to the cells, leading to a diverse array of intracellular signaling events that participate in cell adhesion, spreading and migration (Hood et al., 2003; Yan et al., 2008) . Consistent with the evidence reported previously that MAPK and AKT mediate YKL-40-induced mitogenic signaling in connective tissue cells (Recklies et al., 2002) , our results showed that YKL-40 uses intracellular FAK-MAPK signaling pathways for endothelial cell angiogenesis.
Although YKL-40 is expressed by some tumor lines, the lack of its expression in several breast and colon cancer lines may reflect the fact that selection pressures for establishing these cell lines do not require angiogenesis, and thus the lack of YKL-40 expression exists as an artifact of different cell culture conditions. Furthermore, this deficiency is not an isolated and rare event as a number of other tumor angiogenesispromoting factors such as periostin and SPARC were similarly reported in the literature (Jendraschak and Sage, 1996; Yan and Shao, 2006) . Nevertheless, the fact that a substantial fraction of primary breast tumors express YKL-40 in our study suggests that it is a common pathway in vivo.
A wealth of tumorigenic evidences from both human cancers and animal tumor models indicate that elevated levels of angiogenic factors in cancer tissue correlate with tumor angiogenesis and tumor progression (Kim et al., 1993; Millauer et al., 1996; Polnaszek et al., 2003) . Anti-angiogenic intervention has achieved considerable effectiveness in the suppression of cancer growth and development, which includes monoclonal antibodies against angiogenic factors and synthetic smallmolecule inhibitors specific for membrane receptor kinases or intracellular mediators (Kim et al., 1993; Fahmy et al., 2003) . The present findings that indicate that YKL-40 promotes tumor angiogenesis may hold promise for developing novel therapeutic agents targeting YKL-40 that is overexpressed in a broad range of human cancers.
Materials and methods
Generation of cancer cell lines stably expressing YKL-40
The full length of YKL-40 cDNA was subcloned into a retroviral pCMV-neo-vector. 293T retroviral packaging cells were transfected with YKL-40 or vector control DNA in the presence of pCL 10A1 vector using Fugene 6 as the delivery vehicle. Forty-eight hours after transfection, the supernatant was harvested and filtered through 0.45-mm pore size filter and the virus-containing medium was used to infect to tumor cells. Selection with 800 mg/ml of G418 was initiated 48 h after infection, and the drug-resistant cell populations were used for subsequent studies. S1 and YKL-40 gene knockdown DNA oligos (19 bp) specifically targeting the ectodomain of S1 (Beauvais et al., 2004) , N-terminal (siRNA 1) or C-terminal (siRNA 2) region of YKL-40 were selected, and then templates (64 oligo nucleotides) containing these oligos were subcloned into a retroviral pSUPER-puro-vector. Retroviral media were generated as described above, and the resulting medium was infected to HMVECs or U87 cells to establish the lines stably silencing the S1 or YKL-40 gene, respectively.
Generation of recombinant YKL-40
Full-length human YKL-40 cDNA with a His-tag was subcloned into pFastBac1 vector (Life Technologies, Gaithersburg, MD, USA). After transformation and amplification in DH10Bac Escherichia coli, bacmid DNA containing YKL-40 was transfected into Sf9 insect cells by using CellFECTIN reagent (Invitrogen, Carlsbad, CA, USA) and the baculoviral medium was produced. A Ni-NTA column was used to purify recombinant YKL-40 according to the manufacture's instruction (Invitrogen), and pure YKL-40 was finally produced through a PD-10 desalting column (Amersham Biosciences, Piscataway, NJ, USA).
Heparin-Sepharose affinity binding assay Recombinant YKL-40 (1 mg) was loaded into a heparinSepharose affinity column (Amerham Biosciences) and preequilibrated with 20 mM sodium phosphate buffer (pH 7.4) containing 25 mM NaCl. After washing with 5 volume of the loading buffer, the column was eluted with 20 mM sodium phosphate buffer containing 1 M NaCl. All collected samples were concentrated with centrifugal concentrators before immunoblotting.
Migration assays
Human microvascular endothelial cells (2 Â 10 5 ) were preincubated with serum-free medium for 12 h and transferred into transwells (24-well plates) precoated with collagen IV (100 mg/ml). The lower chamber of transwells included YKL-40 (100 ng/ ml), ySP (100 ng/ml) or VEGF (10 ng/ml). After 4 h of incubation, cells in the top chamber of the transwells membrane were removed using Q-tip. Average cell numbers were calculated from five different fields in each sample. In some experiments, a neutralizing anti-VEGF monoclonal antibody (Sigma, St Louis, MO, USA) was used.
Tube formation assays
Human microvascular endothelial cells (0.1 Â 10 5 cells) were transferred into 96-well Matrigel in the presence of YKL-40 (100 ng/ml), ySP (100 ng/ml) or VEGF (10 ng/ml) (Becton Dickson Lab, Bedford, MA, USA). After 12 h of incubation, tube-forming structures were analysed.
Immunoprecipitation and western blot Cell lysates were prepared as described previously (Yan et al., 2008) . The samples were then incubated overnight with antiintegrin b 3 or b 5 antibody at 4 1C, followed by incubation with protein A Sepharose beads at 4 1C for 2 h. The immunocomplex was extensively washed and the samples were subjected to immunoblots. The primary antibodies against S1, Erk1/2, pErk1/2, FAK (Santa Cruz Biotechnology, Santa Cruz,, CA, USA), FAK pY 397 , FAK pY 861 (Biosource, Camarillo, CA, USA), integrin b 3 and b 5 (Chemicon International, Temecula, CA, USA) and rAY were used to examine protein expressions. Specific signals were detected using an ECL Kit (VWR, Rockford, IL, USA).
Tumor xenografts in mice
All animal experiments were conducted after obtaining the approval of the Institutional Animal Care and Use Committee of the University of Massachusetts. SCID/Beige mice were injected subcutaneously with HCT-116 (4.5 Â 10 6 ), MDA-MB-231 (1.5 Â 10 6 ) or U87 (2 Â 10 6 ) cells in 0.2 ml of Hank's balance buffer without calcium and magnesium. Tumor growth from these injected cells was monitored weekly for 6 weeks before the animals were killed. The tumors were measured and calculated as follows: volume ¼ length Â width 2 Â 0.52.
Immunohistochemistry
The study of breast cancer samples was approved by the University of Massachusetts and Baystate Medical Center Institutional Review Board. Frozen tumor tissues collected from animals were cut into slices of 6-mm thickness and processed for CD31 staining. In brief, the samples were blocked with 3% H 2 O 2 to block endogenous peroxidase activity for 30 min, followed by incubation with blocking buffer containing 10% goat serum for 1 h. The rat anti-CD31 monoclonal antibody (1:500, BD Pharmagen, Mountain View, CA, USA) was then incubated at room temperature for 2 h and goat anti-rat secondary antibody (1:100) conjugated with horseradish peroxidase was added. Finally, DAB (3,3-diaminodbenzidine) substrate (Dako, Carpinteria, CA, USA) was introduced for several minutes and after washing, methyl green was used for counterstaining. Paraffin-embedded human cancer specimens were processed similarly as described above for staining of YKL-40 (1:400) and CD34 (1:200) (Dako). YKL-40 staining was evaluated as combined scores of percentage and intensity of positive staining cells as follows:
(1) percentage: no staining is 0 points, o10% of cells stained is 1 point, 11-50% of cells stained is 2 points and >50% of cells stained is 3 points; (2) intensity: no staining is 0 points, weak staining is 1 point, moderate staining is 2 points and strong staining is 3 points. Thus, the valid range of scores was 0-6.
YKL-40 and tumor angiogenesis R Shao et al
